Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Ruby Khatun Khatun
    Ruby Khatun Khatun
      • Home
      • Ruby Khatun Khatun

      Articles By : Ruby Khatun Khatun

      Kidney Damage: Drug controller bans Voveran injection

      Kidney Damage: Drug controller bans Voveran injection

      Ruby Khatun Khatun13 July 2018 3:55 PM IST
      The Drug Controller General of India (DCGI) further ordered for the withdrawal of the drug's stock from the market.New Delhi: India's drug regulator...
      Sun Pharma unit files patent case against German firm Biofrontera

      Sun Pharma unit files patent case against German firm Biofrontera

      Ruby Khatun Khatun13 July 2018 10:30 AM IST
      PRINCETON, New Jersey and MUMBAI: DUSA Pharmaceuticals, Inc., ("DUSA") a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. announced that...
      Aurobindo Pharma gets USFDA approval for infection treatment drug

      Aurobindo Pharma gets USFDA approval for infection treatment drug

      Ruby Khatun Khatun13 July 2018 10:15 AM IST
      New Delhi: Drug firm Aurobindo Pharma has received final approval from the USFDA to manufacture and market Azithromycin tablets, used for the...
      Lupin, Boehringer Ingelheim to co-market two oral anti-diabetic drugs in India

      Lupin, Boehringer Ingelheim to co-market two oral anti-diabetic drugs in India

      Ruby Khatun Khatun13 July 2018 10:00 AM IST
      New Delhi: Drug major Lupin said it has expanded its collaboration with Germany's Boehringer Ingelheim for co-marketing two oral anti-diabetic drugs...
      MTaI to organise Medical Packaging Seminar on July 16

      MTaI to organise Medical Packaging Seminar on July 16

      Ruby Khatun Khatun13 July 2018 9:45 AM IST
      New Delhi: Medical Technology Association of India (MTaI), an association of research-based medical technology companies who have made significant...
      Trump told Pfizer CEO price hikes hurt his drug plan: source

      Trump told Pfizer CEO price hikes hurt his drug plan: source

      Ruby Khatun Khatun13 July 2018 9:30 AM IST
      NEW YORK/WASHINGTON: U.S. President Donald Trump called Pfizer Chief Executive Ian Read to say the company’s July 1 price hikes had complicated the...
      Mumbai: Patient group opposes hepatitis C drug patent in India

      Mumbai: Patient group opposes hepatitis C drug patent in India

      Ruby Khatun Khatun12 July 2018 5:58 PM IST
      MUMBAI: 2 hepatitis drugs of Gilead Sciences have drawn the attention of patient group over its patent. A patient advocacy and support group called...
      Fortis board to meet on Friday to consider fund raising

      Fortis board to meet on Friday to consider fund raising

      Ruby Khatun Khatun12 July 2018 10:30 AM IST
      New Delhi: Cash-strapped Fortis Healthcare, which is in the process of finding a new investor, on Wednesday said its board will meet on July 13 to...
      Lupin appoints Yashwant Mahadik as Global HR President

      Lupin appoints Yashwant Mahadik as Global HR President

      Ruby Khatun Khatun12 July 2018 10:15 AM IST
      New Delhi: Drug firm Lupin said it has appointed Yashwant Mahadik as President, Global Human Resources.Mahadik will be based in Mumbai and will report...
      Glenmark expands its oncology franchise in India with launch of Helsinns Akynzeo

      Glenmark expands its oncology franchise in India with launch of Helsinn's Akynzeo

      Ruby Khatun Khatun12 July 2018 10:00 AM IST
      New Delhi: Glenmark Pharmaceuticals and Swiss pharma group Helsinn announced the launch of Akynzeo, a fixed dose combination drug for prevention of...
      Mylan launches generic version of Novartis Exelon Patch

      Mylan launches generic version of Novartis Exelon Patch

      Ruby Khatun Khatun12 July 2018 9:45 AM IST
      HERTFORDSHIRE, England and PITTSBURGH: Mylan N.V. announced the U.S. launch of Rivastigmine Transdermal System, 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3...
      Israeli firm gets US nod for advanced trials for non-opiate painkiller

      Israeli firm gets US nod for advanced trials for non-opiate painkiller

      Ruby Khatun Khatun12 July 2018 9:30 AM IST
      JERUSALEM: Israeli pharmaceuticals company PainReform has received approval from the U.S. Food and Drug Administration (FDA) to begin late-stage...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok